Progressive multifocal leukoencephalopathy and natalizumab (Q37885823)

24 August 2017

1 reference

title

Progressive multifocal leukoencephalopathy and natalizumab (English)

1 reference

progressive multifocal leukoencephalopathy

24 August 2017

0 references

2

Ralf Gold

1 reference

24 August 2017

Kerstin Hellwig

1

1 reference

24 August 2017

7 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

258

1 reference

24 August 2017

11

1 reference

24 August 2017

1920-1928

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-011-6116-8

24 August 2017

0 references

cites work

Facial transplantation: brave new face.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

JC virus infection of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Seizures and their outcome in progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Identification and characterization of mefloquine efficacy against JC virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-6116-8

Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

12 December 2020

Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon

1 reference

12 December 2020

10.1007/S00415-011-6116-8

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21647730